Over the past 25 years, physiologically based pharmacokinetic (PBPK) modeling has revolutionized our understanding of drug-drug interactions (DDIs). This retrospective will delve into the profound impact PBPK has had on the field, not only advancing the science and knowledge but also transforming the culture of research groups. By moving away from traditional methods and embracing mechanistic modeling, PBPK has provided a framework for predicting complex DDIs with greater accuracy and insight. This approach has fostered a collaborative mindset, encouraging continuous learning and innovation and a shift from empirical data to rational, model-based predictions. Join us as we explore how PBPK has become an indispensable tool in drug development.
Key takeaways:
- Advanced DDI Prediction: PBPK modeling has significantly improved drug-drug interaction understanding and predictions.
- Cultural Shift: PBPK has fostered a collaborative and innovative research culture.
- Practical Impact: PBPK is essential for understanding complex drug interactions and driving a deeper mechanistic understanding of the drivers of DDI.
講師:
Gemma Louise Dickinson, PhD, Vice President and Head of Global PK/PD and Pharmacometrics at Eli Lilly and Company
Dr. Gemma Louise Dickinson joined Eli Lilly and Company in 2008 as a Research Scientist in the Global PK/PD organization at Erl Wood, UK. She later moved to Indianapolis, where she became Director of Mechanistic Pharmacokinetics and Computational ADME. In 2022, she returned to PK/PD and now serves as Vice President and Head of Global PK/PD and Pharmacometrics, overseeing PK/PD deliverables across the portfolio with teams in the US, UK, Singapore, and Ireland.
A recognized expert in mechanistic pharmacokinetics, Dr. Dickinson holds a bachelor’s degree in Pharmacology and a PhD in Pharmacokinetics from The University of Sheffield. She is passionate about advocating for women in science and mentoring women and girls in STEM.